Elsa Ansari¹, Emmanson Emmanson²*, Sunday Kaura³, Ebele Lauretta Iloanya⁴, Anthonia B Ojomo⁵ and Ololade Comfort Olawoyin⁶

¹Department: Chemistry, University of Sindh Jamshoro, Pakistan
²Sacred Heart College of Nursing Sciences, Pakistan
³Verittas University, Nigeria
⁴Department: Applied Biochemistry, Nnamdi Azikiwe University, Nigeria
⁵Department of Pharmacy, Universite De Parakou, Benin
⁶Biological Science Department, Federal Poly Bida, Nigeria

*Corresponding Author: Emmanson Emmanson, Sacred Heart College of Nursing Sciences, Pakistan.

Received: May 24, 2024; Published: May 31, 2024

Abstract

This study investigates the long-term effects and cellular mechanisms of resveratrol, fisetin, and senolytics on human healthspan and lifespan using animal model studies. The experimental cohort comprised male C57BL/6 mice randomly assigned to treatment groups: resveratrol, fisetin, senolytics, or control. Lifespan was evaluated using Kaplan-Meier survival analysis, revealing significant extensions in mice treated with resveratrol (p < 0.05) and fisetin (p < 0.05) compared to controls, suggesting their potential to enhance longevity. Furthermore, resveratrol and fisetin treatment demonstrated improvements in healthspan indicators, including physical activity levels, cognitive function, metabolic parameters, and age-related pathologies.
Resveratrol-treated mice exhibited increased physical activity levels compared to controls, while fisetin-treated mice showed enhanced cognitive function in spatial memory tasks. Additionally, both resveratrol and fisetin treatment led to improvements in metabolic parameters, such as glucose tolerance and insulin sensitivity, and reductions in age-related pathologies, including inflammation and oxidative damage.
Mechanistic analyses revealed distinct cellular pathways underlying the effects of resveratrol, fisetin, and senolytics. Resveratrol activated sirtuins and AMPK signaling pathways, while fisetin exhibited antioxidant, anti-inflammatory, and neuroprotective properties. Senolytics treatment showed trends in reducing senescent cell burden and attenuating age-related decline in tissue function.
Despite promising findings, limitations include the use of animal models, which may not fully replicate human aging, and the need for further validation in human populations. Additionally, the specific dosages and treatment regimens used may not directly translate to human applications.
Resveratrol, fisetin, and senolytics show promise as interventions for promoting healthy aging and extending lifespan. Further research, including clinical trials in human populations, mechanistic studies, and exploration of combination therapies, is warranted to validate these findings and translate them into clinical practice. Collaborative efforts are crucial to harness the potential of these compounds and improve health outcomes in aging populations.

Keywords: Long-Term Effects; Cellular Mechanisms; Resveratrol; Fisetin; Senolytics; Human Healthspan; Lifespan; Animal Model Studies

References

1. Howitz KT., et al. “Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan”. Nature6954 (2023): 191-196.
2. Pearson KJ., et al. “Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span”. Cell metabolism2 (2008): 157-168.
3. Pallauf K., et al. “Nutrition and healthy ageing: Caloric restriction or polyphenol-rich “MediterrAsian” diet?” Oxidative Medicine and Cellular Longevity (2013).
4. Yousefzadeh MJ., et al. “Fisetin is a senotherapeutic that extends health and lifespan”. EBioMedicine 36 (2018): 18-28.
5. Kirkland JL., et al. “The clinical potential of senolytic drugs”. Journal of the American Geriatrics Society10 (2017): 2297-2301.
6. Ferrucci L., et al. “Aging and multimorbidity: new tasks, priorities, and frontiers for integrated gerontological and clinical research”. The Journals of Gerontology: Series A 4 (2020): 628-629.
7. Baur JA., et al. “Resveratrol improves health and survival of mice on a high-calorie diet”. Nature7117 (2006): 337-342.
8. Hubbard BP., et al. “Evidence for a common mechanism of SIRT1 regulation by allosteric activators”. Science 6124 (2013): 1216-1219.
9. Goh KP., et al. “Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure”. International Journal of Sport Nutrition and Exercise Metabolism1 (2014): 2-13.
10. Yoon G and Park S. “Fisetin extends lifespan of Caenorhabditis elegans through insulin/IGF-1 signaling pathway”. Journal of life science11 (2018): 1206-1212.
11. Niedernhofer LJ., et al. “Recreating aged skin in a dish”. Cell Stem Cell3 (2018):  315-316.
12. Das A., et al. “Impairment of an endothelial NAD+-H2S signaling network is a reversible cause of vascular aging”. Cell 1 (2018): 74-89.
13. Park SK., et al. “Tocotrienols induce apoptosis in breast cancer cell lines via an endoplasmic reticulum stress-dependent increase in extrinsic death receptor signaling”. Breast Cancer Research and Treatment2 (2008): 221-228.
14. Zhang J and Fang L. “Fisetin improves lead-induced neuroinflammation, apoptosis and synaptic dysfunction in mice associated with the AMPK/SIRT1 and autophagy pathway”. Food and Chemical Toxicology 146 (2019): 111847.
15. Ungvari Z., et al. “Pharmacological modulation of vascular aging”. Circulation research7 (2023): 849-867.
16. Strong R., et al. “Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice”. Aging cell4 (2009): 707-716.
17. Liao CY and Kennedy BK. “Mouse models and aging: longevity and progeria”. Current topics in Developmental Biology 109 (2014): 249-285.
18. Zhang X., et al. “Senolytic therapy: a new horizon for elderly pneumonia”. Aging Medicine1 (2017): 10-17.
19. Jia R., et al. “Senolytics in neurodegenerative diseases: is targeting senescent cells the silver bullet?” Neuroscience Letters 731 (2020):
20. Hickson LJ., et al. “Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease”. EBioMedicine 47 (2019):  446-456.

Citation

Citation: Emmanson Emmanson., et al. “A Research on Long-Term Effects and Cellular Mechanisms of Resveratrol, Fisetin, and Senolytics on Human Healthspan and Lifespan: Insights from Animal Model Studies".Acta Scientific Pharmaceutical Sciences 8.6 (2024): 115-124.

Copyright

Copyright: © 2024 Emmanson Emmanson., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.